LAB INTERNATIONAL SECURES $2.22 MILLION FOR DRUG DEVELOPMENT FROM NATIONAL TECHNOLOGY AGENCY OF FINLAND

LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that LAB Pharma, it's drug development subsidiary headquartered in Finland, has secured approximately $2.22 million (1.55 million euros) to support product development.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-20-2005/0004173807&EDATE=)